The SURPASS-4 study investigated the efficacy and safety, with a focus on cardiovascular safety, of the novel dual GIP and GLP-1 RA tirzepatide compared to insulin glargine in adults with T2DM and high cardiovascular risk who had inadequate control with oral antidiabetic agents. Here, GIP is linked to type 2 diabetes mellitus.